Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Expected to Announce Quarterly Sales of $36.27 Million


Share on StockTwits

Equities analysts expect that Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) will report $36.27 million in sales for the current quarter, Zacks reports. Four analysts have provided estimates for Agios Pharmaceuticals’ earnings, with estimates ranging from $33.40 million to $43.19 million. Agios Pharmaceuticals reported sales of $35.44 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 2.3%. The firm is expected to report its next quarterly earnings results before the market opens on Thursday, February 25th.

On average, analysts expect that Agios Pharmaceuticals will report full year sales of $195.44 million for the current year, with estimates ranging from $192.60 million to $202.35 million. For the next fiscal year, analysts expect that the company will post sales of $561.46 million, with estimates ranging from $78.00 million to $1.88 billion. Zacks’ sales averages are a mean average based on a survey of research firms that cover Agios Pharmaceuticals.

A number of analysts have recently weighed in on AGIO shares. BMO Capital Markets decreased their price target on shares of Agios Pharmaceuticals from $57.00 to $50.00 in a research report on Wednesday, December 9th. Royal Bank of Canada dropped their price target on Agios Pharmaceuticals from $59.00 to $66.00 in a research report on Tuesday, December 22nd. Canaccord Genuity reduced their price objective on Agios Pharmaceuticals from $70.00 to $57.00 and set a “buy” rating on the stock in a research note on Monday, December 28th. Zacks Investment Research upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating and set a $42.00 target price for the company in a research note on Tuesday, November 10th. Finally, Cantor Fitzgerald increased their target price on shares of Agios Pharmaceuticals from $68.00 to $79.00 and gave the stock an “overweight” rating in a report on Thursday, November 19th. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $65.50.

AGIO stock traded up $0.33 during trading on Tuesday, reaching $54.17. The stock had a trading volume of 839,459 shares, compared to its average volume of 745,390. The firm has a fifty day moving average price of $49.33 and a 200 day moving average price of $41.89. The company has a market capitalization of $3.76 billion, a P/E ratio of -10.92 and a beta of 1.80. Agios Pharmaceuticals has a 1-year low of $27.77 and a 1-year high of $58.93.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Principal Financial Group Inc. raised its stake in Agios Pharmaceuticals by 533.0% during the 4th quarter. Principal Financial Group Inc. now owns 92,001 shares of the biopharmaceutical company’s stock valued at $3,986,000 after acquiring an additional 77,466 shares in the last quarter. Truist Financial Corp acquired a new stake in Agios Pharmaceuticals in the fourth quarter worth about $276,000. Voloridge Investment Management LLC bought a new position in Agios Pharmaceuticals in the 4th quarter valued at about $689,000. Canada Pension Plan Investment Board bought a new position in Agios Pharmaceuticals in the 4th quarter valued at about $1,017,000. Finally, Nuveen Asset Management LLC increased its stake in Agios Pharmaceuticals by 14.6% during the 4th quarter. Nuveen Asset Management LLC now owns 427,561 shares of the biopharmaceutical company’s stock valued at $18,526,000 after buying an additional 54,487 shares during the period. Hedge funds and other institutional investors own 92.93% of the company’s stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation.

Featured Story: Why do corrections happen?

Get a free copy of the Zacks research report on Agios Pharmaceuticals (AGIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.